Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)

• Status: Completed
• Trial end date: 2012-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Hypothesis:

Sunphenon, a green tea extract containing 95% egcg, given daily as oral medication over a period of 18 months has anti-inflammatory and neuroprotective properties in patients with relapsing-remitting multiple sclerosis as assessed by magnetic resonance imaging and clinical examination (EDSS and MSFC).

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Charite University, Berlin, Germany
• Treatments: Epigallocatechin gallate; Glatiramer Acetate

Criteria

Inclusion Criteria:

• male and female subjects age 18 to 60

• relapsing-remitting course of MS

• stable treatment with glatiramer acetate at least 6 months prior to inclusion

Exclusion Criteria:

• primary or secondary progressive forms of MS

• clinically relevant heart, lung, liver, kidney diseases

• regular hepatotoxic co-medication

• drug addiction

• alcohol abuse